Local and systemic effects of inhaled AZD9164 compared with tiotropium in patients with COPD

Abstract

There is still a need for new agents which improve upon the therapeutic index of tiotropium, the current standard of care for many patients with chronic obstructive pulmonary disease (COPD). We examined in patients with COPD the efficacy of single doses of AZD9164, an M3-selective muscarinic antagonist, to identify an appropriate dose-range for future studies. COPD patients (n = 28) inhaled AZD9164 (100, 400 and 1200 μg), tiotropium (18 μg) and placebo at 5 study centre visits (Clinicaltrials.gov identifier NCT00939211). The effects of these test drugs on average (Eav), peak (Emax) and trough (E22-26) forced expiratory volume in one second (FEV1) were assessed, as were systemically-mediated effects and the safety and exposure of single doses of AZD9164. AZD9164 100, 400 and 1200 μg caused increases in FEV1 to peak effects of 12, 17 and 12% above baseline respectively, following an initial transient and dose-related fall in FEV1 and associated increase in mild respiratory symptoms such as cough. Bronchodilation was maintained overnight, with minimal FEV 1 decline. AZD9164 400 and 1200 μg produced larger effects than tiotropium on E22-26 (p < 0.05; both doses) while AZD9164 400 μg also had larger effects on Emax (p = 0.001) and Eav (p < 0.05). There were no serious adverse events and statistically significant systemic effects were observed only with AZD9164 1200 μg. AZD9164 may improve upon the therapeutic index of tiotropium, increasing the magnitude and duration of lung function improvements without increasing systemically-mediated adverse events. The initial bronchoconstrictor effect of AZD9164 requires further investigation. © 2012 Published by Elsevier Ltd.